By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CureVac GmbH 

Paul-Ehrlich-Str. 15

Tübingen    72076  Germany
Phone: 49-7071-92053-0 Fax: 49-7071-92053-11


SEARCH JOBS


Industry
Biotechnology






Company News
CureVac Announces Phase I/IIa Clinical Study Data Of Its mRNA Cancer Immunotherapy In Prostate Cancer Published In The Journal For Immunotherapy Of Cancer 7/7/2015 6:25:00 AM
CureVac Announces Study Publication In Molecular Therapy Demonstrating Wide-Ranging Benefits Of Sequence-Optimized, Unmodified mRNAs 6/24/2015 6:39:50 AM
Bill & Melinda Gates Foundation Injects $52 Million Into CureVac 3/5/2015 2:34:09 PM
Boehringer Ingelheim Corporation Will Pay Up To $600 Million For CureVac GmbH Lung Cancer Vaccine 9/18/2014 6:21:48 AM
CureVac GmbH, Sanofi (France) (SAN.PA) Strike €150.5 Million+ Vaccine Pact 7/1/2014 7:30:41 AM
CureVac GmbH Completes Patient Recruitment For Phase 2 Clinical Trial Of Mrna-Based Prostate Cancer Treatment 12/16/2013 9:26:35 AM
CureVac GmbH Release: 1st International mRNA Health Conference in Tuebingen Heralds a New Era in Modern Medicine 11/5/2013 8:48:26 AM
CureVac GmbH Collaborates With the Cancer Research Institute and Ludwig Institute For Cancer Research (LICR) to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer 11/4/2013 10:37:24 AM
CureVac GmbH to Collaborate With Janssen Pharmaceutical Inc. of mRNA-Based Influenza Vaccine 10/3/2013 9:03:59 AM
CureVac GmbH Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer 3/27/2013 8:03:13 AM
12
//-->